Lead Product(s) : Ropanicant
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Suven Life Sciences Announces Positive Phase-2 Results for Ropanicant
Details : SUVN-911 (ropanicant) is a nAChR-alpha4 & beta2 inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of moderate to severe major depressive disorder.
Brand Name : SUVN-911
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 18, 2024
Lead Product(s) : Ropanicant
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?